Mathias Wenes
Company: MPC therapeutics
Job title: Head of Immunotherapy
Seminars:
Increasing the Fitness & Durability of T-Cell Therapies Using the Novel Small Molecule MITO-66 Targeting Mitochondrial Metabolism 12:40 pm
Overview of MPC Therapeutics’ approach to target the mitochondrial pyruvate carrier (MPC) to reprogramme CAR-T cell metabolism Pre-clinical data showing that MPC inhibition during manufacturing dramatically improves CAR-T cell efficacy and durability Opportunities to integrate MPC inhibition into a clinical manufacturing pipelineRead more
day: Day 2 - Track A - AM